Alex Biese

At the 10th Annual School of Nursing Oncology, faculty said nurses need fast, disease-specific updates to educate patients and manage novel therapies.

Experts detail evidence for exercise, acupuncture, and mind-body care during radiation, and the knowledge and referral gaps that limit uptake.

Jessica Miles, MS, RN, CNS, explains how bench testing showed pumps and filters did not compromise stem cell infusion safety.

Daisy Molina, EdD, MSN, RNC-LRN, discusses listening, honest reassurance, and lifelong communication skills for nurses facing hard conversations.

A patient, a caregiver, nurses, an NP, and an oncologist discuss rash prevention, dose holds, cost, and trial eligibility with oral daraxonrasib.

Daisy Molina, EdD, MSN, RNC-LRN, explains how nurses can include caregivers in breast cancer care while keeping the patient's voice central.

Daisy Molina, EdD, MSN, RNC-LRN, details how nursing students learn to deliver hard news with empathy, plain language, and team support.

At the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.

Kate Kennedy, MSN, APRN, explains how Vanderbilt-Ingram's award-winning APP clinic moved bispecific step-up dosing out of the hospital.

Nurses and NPs share how they manage rash, stomatitis, diarrhea, dose holds, cost, and trial eligibility with oral daraxonrasib in pancreatic cancer.

Nicole Doell, MSN, RN, of Sylvester explains how nurses can address breast cancer misinformation without judgment and share vetted resources.

Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.

Sylvester's Nicole Doell, MSN, RN, discusses how oncology nurses can support patients with breast cancer emotionally, from diagnosis to survivorship.

Suzanne E. Barron, CRNP, explains how education, premedication, and pharmacy coordination streamline intravesical gene therapy treatment days.

Dana-Farber nurse practitioners reflect on cross-country networking, resource gaps, and ADC education needs after JADPRO Live 2026.

A Fox Chase intervention raised trial-naïve patients' understanding of placebo use and randomization; its effect on enrollment is still untested.

Yingzi Zhang, PhD, RN, discusses anxiety and depression data from 21,206 oncology patients ahead of the ANE Research Symposium.

A breast surgeon explains how nurses can build baseline bioimpedance screening and long-term lymphedema surveillance into clinic workflows.

Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.

Brianne Whitley, CNP, of Dana-Farber, shares strategies for hot flashes, sexual health, survivorship planning, and clinical trial access for men.

Dana-Farber's Brianne Whitley, CNP, details red-flag symptoms, ER-positive biology, and why every man with breast cancer needs a genetic referral.

Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.

Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.

A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.

FDA-approved subcutaneous isatuximab via on-body injector changes myeloma care workflows. Experts outline what nurses and PAs need to know.

For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.

Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.

In a randomized trial, 73% of relatives offered navigation completed genetic testing within 6 months vs 51% of those who received a family letter.

In observation of National PA Week, Moffitt PA Mark Honor details top-of-license nursing collaboration and outpatient end-stage hematology care.

Beth Faiman, PhD, CNP, details the new IMS/IMWG consensus definition of cure for multiple myeloma, which requires 5 years of treatment-free remission.